94437-04-4

Basic information

• Product Name: (1,4-Dibenzyl-piperazin-2-yl)-Methanol
• Synonyms: (1,4-Dibenzyl-piperazin-2-yl)-Methanol
• CAS NO: 94437-04-4
• Molecular Formula: C₁₉H₂₄N₂O
• Molecular Weight: 296.40666
• Mol File: 94437-04-4.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1,4-Dibenzyl-piperazin-2-yl)-Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1,4-Dibenzyl-piperazin-2-yl)-Methanol(94437-04-4)
• EPA Substance Registry System: (1,4-Dibenzyl-piperazin-2-yl)-Methanol(94437-04-4)

Safety Data

• Hazardous Substances Data: 94437-04-4(Hazardous Substances Data)

Usage

General Description

(1,4-Dibenzyl-piperazin-2-yl)-Methanol is a chemical compound with the molecular formula C21H24N2O. It is a derivative of piperazine, a heterocyclic compound with a six-membered ring containing two nitrogen atoms. The presence of benzyl groups in the molecule indicates potential for biological activity, as benzyl compounds have been shown to possess antimicrobial and antiparasitic properties. However, the specific properties and potential uses of (1,4-Dibenzyl-piperazin-2-yl)-Methanol have not been extensively studied and further research is necessary to determine its potential applications in pharmaceuticals or other industries.

Upstream product

• 72351-59-8 ethyl 1,4-dibenzylpiperazin-2-carboxylate 
• 104-71-2 N,N'-bis(benzyliden)ethylendiamine 
• 100-52-7 benzaldehyde 
• 54969-33-4 1,4-dibenzyl-piperazine-2-carboxylic acid methyl ester 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 253781-48-5 phenylmethyl 1,4-bis(phenylmethyl)-2-piperazinecarboxylate 

Downstream Products

• 148227-88-7 2,2-Dimethyl-propionic acid 1,4-dibenzyl-piperazin-2-ylmethyl ester 
• 148227-92-3 2-Chloro-benzoic acid 1,4-dibenzyl-piperazin-2-ylmethyl ester 
• 111760-58-8 1,4-dibenzyl-2-hexoxymethyl-piperazine 
• 253781-49-6 2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-1,4-bis(phenylmethyl)piperazine 
• 129230-09-7 N,N'-dibenzyl 2-cyclohexylcarbonyloxymethyl piperazine 
• 111760-36-2 2-fluoromethyl-1,4-di-phenylmethyl piperazine 
• 111760-25-9 2-dimethylaminomethyl-1,4-bis(phenylmethyl)piperazine 
• 914654-88-9 1,1-dimethylethyl (RS)-[1,4-bis(phenylmethyl)-2-piperazinemethoxy]acetate 
• 769159-55-9 1,4-dibenzyl-2-[1,2,4]triazol-1-ylmethylpiperazine 
• 368441-98-9 methyl piperazin-2-ylacetate 
• 183742-32-7 1,4-dibenzyl-2-methoxycarbonylmethylpiperazine 
• 148227-82-1 Acetic acid 1,4-dibenzyl-piperazin-2-ylmethyl ester 
• 1060720-22-0 C₃₄H₃₂ClN₃O 
• 1060720-14-0 (+/-)-1,4-dibenzyl-2-methoxymethylpiperazine hydrochloride 

Relevant articles and documents

Design, synthesis and evaluation against Mycobacterium tuberculosis of azole piperazine derivatives as dicyclotyrosine (cYY) mimics

Three series of azole piperazine derivatives that mimic dicyclotyrosine (cYY), the natural substrate of the essential Mycobacterium tuberculosis cytochrome P450 CYP121A1, were prepared and evaluated for binding affinity and inhibitory activity (MIC) against M. tuberculosis. Series A replaces one phenol group of cYY with a C3-imidazole moiety, series B includes a keto group on the hydrocarbon chain preceding the series A imidazole, whilst series C explores replacing the keto group of the piperidone ring of cYY with a CH2-imidazole or CH2-triazole moiety to enhance binding interaction with the heme of CYP121A1. The series displayed moderate to weak type II binding affinity for CYP121A1, with the exception of series B 10a, which displayed mixed type I binding. Of the three series, series C imidazole derivatives showed the best, although modest, inhibitory activity against M. tuberculosis (17d MIC = 12.5 μg/mL, 17a 50 μg/mL). Crystal structures were determined for CYP121A1 bound to series A compounds 6a and 6b that show the imidazole groups positioned directly above the haem iron with binding between the haem iron and imidazole nitrogen of both compounds at a distance of 2.2 ?. A model generated from a 1.5 ? crystal structure of CYP121A1 in complex with compound 10a showed different binding modes in agreement with the heterogeneous binding observed. Although the crystal structures of 6a and 6b would indicate binding with CYP121A1, the binding assays themselves did not allow confirmation of CYP121A1 as the target.

Quinoline derivatives as neurokinin receptor antagonists

The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R1, R2, R3, R4, R5, X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS

The present invention relates to 11-(piperazin-l-yl)dibenzo[b,f][l,4]oxazapine compounds of the formula I (I) where the variables are as defined herein, their salts and pharmaceutically acceptable compositions thereof. Methods of preparing these compounds are also described. These compounds may be used in the treatment of disorders such as schizophrenia, treatment resistant schizophrenia, bipolar disorder, psychotic depression, treatment resistant depression, schizophrenia-associated depression, treatment resistant OCD, autism, senile psychosis, psychotic dementia, L-DOPA induced psychosis, psychogenic polydipsia, psychotic symptoms of neurological disorders, sleep disorders.